806 related articles for article (PubMed ID: 19443425)
1. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
Bartha E; Solti I; Kereskai L; Lantos J; Plozer E; Magyar K; Szabados E; Kálai T; Hideg K; Halmosi R; Sumegi B; Toth K
Cardiovasc Res; 2009 Aug; 83(3):501-10. PubMed ID: 19443425
[TBL] [Abstract][Full Text] [Related]
2. PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.
Deres L; Bartha E; Palfi A; Eros K; Riba A; Lantos J; Kalai T; Hideg K; Sumegi B; Gallyas F; Toth K; Halmosi R
PLoS One; 2014; 9(7):e102148. PubMed ID: 25014216
[TBL] [Abstract][Full Text] [Related]
3. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Palfi A; Toth A; Hanto K; Deres P; Szabados E; Szereday Z; Kulcsar G; Kalai T; Hideg K; Gallyas F; Sumegi B; Toth K; Halmosi R
J Mol Cell Cardiol; 2006 Jul; 41(1):149-59. PubMed ID: 16716347
[TBL] [Abstract][Full Text] [Related]
4. A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats.
Magyar K; Deres L; Eros K; Bruszt K; Seress L; Hamar J; Hideg K; Balogh A; Gallyas F; Sumegi B; Toth K; Halmosi R
Biochim Biophys Acta; 2014 Jul; 1842(7):935-44. PubMed ID: 24657811
[TBL] [Abstract][Full Text] [Related]
5. Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
Bartha E; Kiss GN; Kalman E; Kulcsár G; Kálai T; Hideg K; Habon T; Sumegi B; Toth K; Halmosi R
J Cardiovasc Pharmacol; 2008 Sep; 52(3):253-61. PubMed ID: 18806606
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats.
Geng J; Zhao Z; Kang W; Wang W; Zhang Y; Zhiming GE
Pharmacol Res; 2010 Jan; 61(1):40-7. PubMed ID: 19683055
[TBL] [Abstract][Full Text] [Related]
8. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
Gao S; Long CL; Wang RH; Wang H
Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
[TBL] [Abstract][Full Text] [Related]
9. BGP-15 Protects against Heart Failure by Enhanced Mitochondrial Biogenesis and Decreased Fibrotic Remodelling in Spontaneously Hypertensive Rats.
Horvath O; Ordog K; Bruszt K; Deres L; Gallyas F; Sumegi B; Toth K; Halmosi R
Oxid Med Cell Longev; 2021; 2021():1250858. PubMed ID: 33564362
[TBL] [Abstract][Full Text] [Related]
10. Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.
Bartha E; Solti I; Szabo A; Olah G; Magyar K; Szabados E; Kalai T; Hideg K; Toth K; Gero D; Szabo C; Sumegi B; Halmosi R
J Cardiovasc Pharmacol; 2011 Oct; 58(4):380-91. PubMed ID: 21697725
[TBL] [Abstract][Full Text] [Related]
11. Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion.
Kovacs K; Toth A; Deres P; Kalai T; Hideg K; Gallyas F; Sumegi B
Biochem Pharmacol; 2006 Feb; 71(4):441-52. PubMed ID: 16337154
[TBL] [Abstract][Full Text] [Related]
12. Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.
Eros K; Magyar K; Deres L; Skazel A; Riba A; Vamos Z; Kalai T; Gallyas F; Sumegi B; Toth K; Halmosi R
PLoS One; 2017; 12(3):e0174401. PubMed ID: 28339485
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial protective effects of PARP-inhibition in hypertension-induced myocardial remodeling and in stressed cardiomyocytes.
Ordog K; Horvath O; Eros K; Bruszt K; Toth S; Kovacs D; Kalman N; Radnai B; Deres L; Gallyas F; Toth K; Halmosi R
Life Sci; 2021 Mar; 268():118936. PubMed ID: 33421523
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress.
Oudit GY; Kassiri Z; Zhou J; Liu QC; Liu PP; Backx PH; Dawood F; Crackower MA; Scholey JW; Penninger JM
Cardiovasc Res; 2008 Jun; 78(3):505-14. PubMed ID: 18281373
[TBL] [Abstract][Full Text] [Related]
15. Effect of oxymatrine, the active component from Radix Sophorae flavescentis (Kushen), on ventricular remodeling in spontaneously hypertensive rats.
Huang XY; Chen CX
Phytomedicine; 2013 Feb; 20(3-4):202-12. PubMed ID: 23211799
[TBL] [Abstract][Full Text] [Related]
16. IcarisideII improves left ventricular remodeling in spontaneously hypertensive rats by inhibiting the ASK1-JNK/p38 signaling pathway.
Wu Y; Qian Z; Fu S; Yue Y; Li Y; Sun R; Huang B; Yang D
Eur J Pharmacol; 2018 Jan; 819():68-79. PubMed ID: 29175071
[TBL] [Abstract][Full Text] [Related]
17. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice.
Wang AW; Song L; Miao J; Wang HX; Tian C; Jiang X; Han QY; Yu L; Liu Y; Du J; Xia YL; Li HH
Am J Hypertens; 2015 Apr; 28(4):518-26. PubMed ID: 25362112
[TBL] [Abstract][Full Text] [Related]
18. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases.
Sarszegi Z; Bognar E; Gaszner B; Kónyi A; Gallyas F; Sumegi B; Berente Z
Mol Cell Biochem; 2012 Jun; 365(1-2):129-37. PubMed ID: 22350755
[TBL] [Abstract][Full Text] [Related]
19. Compromised mitochondrial remodeling in compensatory hypertrophied myocardium of spontaneously hypertensive rat.
Tang Y; Mi C; Liu J; Gao F; Long J
Cardiovasc Pathol; 2014; 23(2):101-6. PubMed ID: 24388463
[TBL] [Abstract][Full Text] [Related]
20. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
